Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Frequently asked questions
What sector does Braveheart Bio, Inc. Common Stock (BRVE) operate in?
Braveheart Bio, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Braveheart Bio, Inc. Common Stock (BRVE) current stock price?
As of the latest data, Braveheart Bio, Inc. Common Stock stock price is $21.87, with a previous close of $21.44. Braveheart Bio, Inc. Common Stock gained $0.43 in the last trading session, representing a 2.01% increase.
What is Braveheart Bio, Inc. Common Stock (BRVE) current market capitalization?
Braveheart Bio, Inc. Common Stock market cap is approximately 1.97 billion.
What is Braveheart Bio, Inc. Common Stock (BRVE) Earnings Per Share (EPS)?
The trailing EPS is -$6.08, and the forward EPS is -$1.62.
What is Braveheart Bio, Inc. Common Stock (BRVE) EBITDA?
Braveheart Bio, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.88 million.
Does Braveheart Bio, Inc. Common Stock (BRVE) pay dividends?
No. Braveheart Bio, Inc. Common Stock does not pay a dividend.
When is Braveheart Bio, Inc. Common Stock (BRVE) next earnings report?
Braveheart Bio, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Braveheart Bio, Inc. Common Stock (BRVE) beta (volatility) score?
Braveheart Bio, Inc. Common Stock has a beta of 0.009, indicating lower volatility than the overall market.
